The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Tag Archives: Kane Biotech

Monday Deal Review: February 24, 2014

  Welcome to your Monday Biotech Deal Review for February 24, 2014!

Read more of this post

Monday Deal Review: February 10, 2014

  Welcome to your Monday Biotech Deal Review for February 10, 2014! The big news this week was Valeant’s proposed acquisition of another skin care innovator, PreCision Dermatology, for $475 million. Hit the break for more details on this as well as the rest of the week’s major biotech news.

Read more of this post

Monday Deal Review: December 17, 2012

Welcome to your Monday Biotech Deal Review for December 17, 2012.  This week saw the completion of a number of previously announced acquisitions, as well as the announcement of new ones. The latter group includes Gilead’s acquisition of YM Biosciences and Helix’s sale of Rivex to Pharmascience. See the details on these major transactions, as well as the past week’s other biotech news, by clicking through.

Read more of this post

Monday Deal Review: November 19, 2012

Welcome to your Monday Biotech Deal Review for November 19, 2012. This past week saw the FTC give Valeant formal approval to acquire Medicis. A busy week on the investment front saw Kane Biotech, Lignol and MethylGene announce their intentions to raise capital. We also saw Abattis executing their previously announced licensing agreement with Vertical Design Systems for the use of Vertical’s plants, plant materials and extracts production technology. For more details on these sotries as well as many more, click through below!  
Read more of this post

Monday Deal Review: October 29, 2012

Welcome to your Monday Biotech Deal Review for October 29, 2012.  Last week, we saw Warnex agree to sell their Bioanalytics Division, which specializes in bioavailability and bioequivalence analysis for pre-clinical and clinical studies, to France-based Biotrial Research. Calyx Bio-Ventures also had a busy week, not only announcing their intent to raise up to $5 million through provate placement, but also that they will be increasing their existing minority stake in Agrisoma Biosciences. For more detail on these stories as well as many more, read on!   
Read more of this post

Monday Deal Review: October 15, 2012

Welcome to your Monday Biotech Deal Review for October 15, 2012.  Thanks to Thanksgiving for the Canadians and Columbus day for the Americans out there, this week’s post covers the last two weeks of activity.  Biggest of the weeks’ stories, however, is Aeterna Zentaris Inc.’s $15 million public offering, closing in mid October.  Read onwards to see just how busy this fall the market is shaping up to be. 
Read more of this post

Monday Biotech Deal Review: January 23, 2012

Welcome to your Monday Biotech Deal Review for January 23, 2012.  Noteworthy news from the previous week include the sweetening of the offer by Valeant for ISTA Pharmaceuticals by an additional dollar per share ($7.50 from $6.50), and the adoption by ISTA of a shareholder rights plan to replace its recently expired plan.  Read on to learn more.  Read more of this post

Monday Biotech Deal Review: November 14, 2011

Welcome to your Monday Biotech Deal Review for November 14, 2011, marking the end of its one month hiatus.  The Monday Biotech Deal Review will now be resuming its normal weekly schedule.  Below are summaries of recent transactions over the past month, which includes the acquisition of Afexa by Valeant for $0.85 per Afexa share, in cash.    Read on to learn more.  Read more of this post

Monday Biotech Deal Review: July 25, 2011

Welcome to your Monday Biotech Deal Review for July 25, 2011.  Interesting tidbits from last week included the termination of the letter of intent relating to the proposed reverse-takeover transaction between Bradmer Pharmaceuticals and P1 Energy Corp., a distribution and marketing agreement between Valeant and Sanofi-aventis Canada, a $15M loan agreement between Protox Therapeutics and Oxford Finance LLC, the filing of a preliminary short-form base shelf prospectus in the Canada and U.S. by YM BioSciences, the closing of a $7M financing round for gIcare Pharma Inc., and the acquisition by Paladin Labs of a significant number of common shares of Afexa Life Sciences.  Read on to learn more.  Read more of this post

Monday Biotech Deal Review: June 6, 2011

Welcome to your Monday Biotech Deal Review for June 6, 2011.  This week’s deal review is brought to you by Norton Rose OR LLP summer student Steven Zuccarelli who, before entering law school at Osgoode Hall Law School, obtained his B.Sc and M.Sc at McMaster University in Biochemistry and Health Sciences, respectively, where he was involved in researching peptide vaccine models.  Steven will be assisting over the summer months with the Monday Deal Review, and it’s great to have him aboard. 

Aside from some interesting commercial deals, as well as CardioComm’s related-party announcement of a $788k asset purchase, things were fairly slow last week.  Read on to learn more. 

Read more of this post

Monday Biotech Deal Review: April 18, 2011

Welcome to your Monday Biotech Deal Review for April 18, 2011.  Just by way of FYI, readers may be interested to know that The Canadian Institute will be hosting its 5th annual conference on Drug Pricing and Reimbursement in Canada in Toronto from June 14 – 15 at the Sutton Place Hotel.  The conference aims to bring key stakeholders together to share perspectives and strategies on maintaining competitiveness and compliance in these difficult markets.  Stay tuned on crossborderbiotech for coverage from the conference.  Back to the deal review, there was a fair bit of commercial activity last week, with some interesting licensing and commercial transactions announced or closed.  Read on to learn more.     Read more of this post

Monday Biotech Deal Review: April 11, 2011

Welcome to your Monday Biotech Deal Review for April 11, 2011.  Notable events in the Canadian biotech space over the past week included: (i) the filing by Valeant with the SEC of a consent solicitation statement in furtherance of its efforts to replace the board of its hostile target Cephalon; (ii) the approval by creditors of the plan put forward by Angiotech in respect of its restructuring and the sanctioning of the plan by courts in Canada and the U.S.; (iii) the closing of a $34.5M private placement by MethylGene; and (iv) the resignation of the board of directors of Ambrilia and the seeking by Ambrilia to pursue insolvency proceedings under the Bankruptcy statute as opposed to creditor protection under the CCAA.  Read on to learn more.  Read more of this post

Monday Biotech Deal Review: April 4, 2011

Welcome to your Monday Biotech Deal Review for April 4, 2011.  Valeant was a major headline last week with its hostile $5.7 billion leveraged-buyout offer for Cephalon, Inc., which some are suggesting may herald a new era of M&A activity in the biotech sector (you’ll recall that Valeant itself is the product of the recent merger with biotech heavyweight Biovail Corporation).   In addition, CCAA-protected Angiotech has filed a second amended and restated plan of compromise or arrangement and has made amendments to its support agreements, which plan is scheduled to be voted by creditors this week.  Last week continued the previous weeks’ pick-up in financing, with some newly announced and closed private placements.  And to top it off there were also a number of interesting commercial and licensing transactions.  Read on to learn more.   Read more of this post

Monday Biotech Deal Review: February 14, 2011

Welcome to the Monday Biotech Deal Review for February 14, 2011.  Aside from the usual assortment of corporate and regulatory announcements over the week, the highlights include SemBioSys’ proposed $4M secured 7% bond issuance, Angiotech’s fifth extension to deadlines under its recapitalization support agreements (and definitive agreements in respect of up to $28M in DIP financing), Med Biogene is being accused of breaching confidentiality and exclusivity agreements and former biotech Bradmer Pharmaceuticals is migrating to the oil and gas industry via a proposed reverse takeover.  Read on to learn more.   Read more of this post

Monday Biotech Deal Review: January 31, 2011

Welcome to your Monday Biotech Deal Review for January 31, 2011.  Angiotech has voluntarily entered into CCAA proceedings and will continue its restructuring efforts there.  There was also some investment activity involving government agencies in Ontario, Quebec and Prince Edward Island.  Read on to learn more, as well as the usual assortment of biotech news reviews from the past week.  Read more of this post

Monday Biotech Deal Review: January 24, 2010

Welcome to your Monday Biotech Deal Review for January 24, 2010.  Despite a slow financing week, there were a few operational announcements as well as awards granted to Canadian biotech companies by the NIH and the UK’s Medical Research Council.  Read on to learn more.  Read more of this post

Monday Biotech Deal Review: January 17, 2011

Welcome to your Monday Biotech Deal Review for January 17, 2011.  Among other things, the past week saw a third extension of deadlines for Angiotech’s debt restructuring efforts, a management-approved take-over bid of WEX Pharmaceuticals, and American DARPA money being spent on Medicago for the development of a H5N1 vaccine.  Read on to learn more.   Read more of this post

Monday Biotech “Happy Holidays” Deal Review: December 27, 2010

Welcome to your Monday Biotech “Happy Holidays” Deal Review!  For those who may have noticed, last week the Monday Biotech Deal Review took its own holiday, so this week’s digest contains biotech news spanning the past two weeks – to ensure you don’t miss a single drummer boy’s beat.  It has been a busy two weeks, with a notable $40M public offering by YM BioSciences of common shares that was announced, priced and closed, as well as an update by Angiotech with respect to its debt restructuring efforts.  There have also been some interesting strategic partnerships and licensing activity over the break.  Read on to learn more.     Read more of this post

Monday Biotech Deal Review: October 4, 2010

This week’s Monday Deal Review brings you the usual assortment of biotech wheelings and dealings from the past week, including a summary of the newly completed Valeant / Biovail merger.  Read more of this post

Monday Biotech Deal Review: January 25, 2010

Everyone’s looking to the future in this week’s deal review: two special committees, 225,000 options, two royalty streams, a delisting notice and the first income trust/tax loss deal of 2010.  Read more of this post

Follow

Get every new post delivered to your Inbox.

Join 126 other followers